Products
XPro™ Protein Therapeutic Candidates
Protein therapeutics are exceptionally potent, safe and address a range of previously unmet needs. XPro™ technology has also allowed us to create a portfolio of candidates consisting of naturally occurring proteins that are engineered for superior therapeutic properties including selectivity, extended half-life, stability and optimized production. One such candidate, a cytokine with improved physical properties, has been licensed to Eli Lilly for development. Xencor has a growing patent portfolio of such candidates for partnering and future exploitation.
Xencor's pipeline is exemplified by a class of precisely engineered protein therapeutic drugs to address the TNF superfamily, a rich class of drug targets that have been implicated in many life threatening human diseases. These product candidates combat autoimmune and inflammatory diseases, such as rheumatoid arthritis, using a proprietary "dominant negative" (DN) mechanism of action. Distinct from existing soluble receptor and neutralizing antibody approaches, DN technology can be applied to all members of the TNF superfamily.